

Houssein Ayoub

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/8384037/houssein-ayoub-publications-by-year.pdf>

Version: 2024-04-23

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

76
papers

1,612
citations

21
h-index

38
g-index

83
ext. papers

3,559
ext. citations

13.7
avg, IF

5.13
L-index

#	Paper	IF	Citations
76	Relative infectiousness of SARS-CoV-2 vaccine breakthrough infections, reinfections, and primary infections.. <i>Nature Communications</i> , 2022 , 13, 532	17.4	13
75	Methods and indicators to validate country reductions in incidence of hepatitis C virus infection to elimination levels set by WHO.. <i>The Lancet Gastroenterology and Hepatology</i> , 2022 ,	18.8	1
74	Human herpes simplex virus-6 (HHV-6) detection and seroprevalence among Qatari nationals and immigrants residing in Qatar. <i>IJID Regions</i> , 2022 , 2, 90-95		
73	Protection against the Omicron Variant from Previous SARS-CoV-2 Infection.. <i>New England Journal of Medicine</i> , 2022 ,	59.2	52
72	Characterizing the effective reproduction number during the COVID-19 pandemic: Insights from Qatar's experience.. <i>Journal of Global Health</i> , 2022 , 12, 05004	4.3	0
71	Effect of mRNA Vaccine Boosters against SARS-CoV-2 Omicron Infection in Qatar.. <i>New England Journal of Medicine</i> , 2022 ,	59.2	36
70	Modeling the population-level impact of treatment on COVID-19 disease and SARS-CoV-2 transmission.. <i>Epidemics</i> , 2022 , 39, 100567	5.1	
69	Analyzing inherent biases in SARS-CoV-2 PCR and serological epidemiologic metrics.. <i>BMC Infectious Diseases</i> , 2022 , 22, 458	4	0
68	Duration of mRNA vaccine protection against SARS-CoV-2 Omicron BA.1 and BA.2 subvariants in Qatar. <i>Nature Communications</i> , 2022 , 13,	17.4	12
67	Assessment of the Risk of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Reinfection in an Intense Reexposure Setting. <i>Clinical Infectious Diseases</i> , 2021 , 73, e1830-e1840	11.6	99
66	Introduction and expansion of the SARS-CoV-2 B.1.1.7 variant and reinfections in Qatar: A nationally representative cohort study.. <i>PLoS Medicine</i> , 2021 , 18, e1003879	11.6	19
65	BNT162b2 and mRNA-1273 COVID-19 vaccine effectiveness against the SARS-CoV-2 Delta variant in Qatar. <i>Nature Medicine</i> , 2021 ,	50.5	104
64	Estimates of global SARS-CoV-2 infection exposure, infection morbidity, and infection mortality rates in 2020. <i>Global Epidemiology</i> , 2021 , 3, 100068	2.3	5
63	Severity, criticality, and fatality of the SARS-CoV-2 Beta variant. <i>Clinical Infectious Diseases</i> , 2021 ,	11.6	8
62	SARS-CoV-2 infection rates in arriving air Travelers in Qatar. <i>Journal of Travel Medicine</i> , 2021 ,	12.9	1
61	Waning of BNT162b2 Vaccine Protection against SARS-CoV-2 Infection in Qatar. <i>New England Journal of Medicine</i> , 2021 , 385, e83	59.2	226
60	Association of Prior SARS-CoV-2 Infection With Risk of Breakthrough Infection Following mRNA Vaccination in Qatar. <i>JAMA - Journal of the American Medical Association</i> , 2021 , 326, 1930-1939	27.4	45

59	Characterizing the Qatar advanced-phase SARS-CoV-2 epidemic. <i>Scientific Reports</i> , 2021 , 11, 6233	4.9	57
58	Epidemiological impact of prioritising SARS-CoV-2 vaccination by antibody status: mathematical modelling analyses. <i>BMJ Innovations</i> , 2021 , 7, 327-336	1.8	15
57	Vulnerability of Syrian refugees in Lebanon to COVID-19: quantitative insights. <i>Conflict and Health</i> , 2021 , 15, 13	4	9
56	Epidemiological Differences in the Impact of COVID-19 Vaccination in the United States and China. <i>Vaccines</i> , 2021 , 9,	5.3	9
55	Analytic Characterization of the Herpes Simplex Virus Type 2 Epidemic in the United States, 1950-2050. <i>Open Forum Infectious Diseases</i> , 2021 , 8, ofab218	1	2
54	Herd Immunity against Severe Acute Respiratory Syndrome Coronavirus 2 Infection in 10 Communities, Qatar. <i>Emerging Infectious Diseases</i> , 2021 , 27, 1343-1352	10.2	38
53	Pfizer-BioNTech mRNA BNT162b2 Covid-19 vaccine protection against variants of concern after one versus two doses. <i>Journal of Travel Medicine</i> , 2021 , 28,	12.9	33
52	SARS-CoV-2 antibody-positivity protects against reinfection for at least seven months with 95% efficacy. <i>EClinicalMedicine</i> , 2021 , 35, 100861	11.3	77
51	mRNA-1273 COVID-19 vaccine effectiveness against the B.1.1.7 and B.1.351 variants and severe COVID-19 disease in Qatar. <i>Nature Medicine</i> , 2021 , 27, 1614-1621	50.5	144
50	Mathematical modeling of the SARS-CoV-2 epidemic in Qatar and its impact on the national response to COVID-19. <i>Journal of Global Health</i> , 2021 , 11, 05005	4.3	40
49	SARS-CoV-2 infection hospitalization, severity, criticality, and fatality rates in Qatar. <i>Scientific Reports</i> , 2021 , 11, 18182	4.9	22
48	Hepatitis C Virus in the Middle East and North Africa 2021 , 3027-3052		
47	Characterizing key attributes of COVID-19 transmission dynamics in China's original outbreak: Model-based estimations. <i>Global Epidemiology</i> , 2020 , 2, 100042	2.3	17
46	Characterizing the historical role of parenteral antischistosomal therapy in hepatitis C virus transmission in Egypt. <i>International Journal of Epidemiology</i> , 2020 , 49, 798-809	7.8	7
45	Epidemiological Impact of Novel Preventive and Therapeutic HSV-2 Vaccination in the United States: Mathematical Modeling Analyses. <i>Vaccines</i> , 2020 , 8,	5.3	6
44	Epidemiological Impact of SARS-CoV-2 Vaccination: Mathematical Modeling Analyses. <i>Vaccines</i> , 2020 , 8,	5.3	51
43	Age could be driving variable SARS-CoV-2 epidemic trajectories worldwide. <i>PLoS ONE</i> , 2020 , 15, e0237959	3.7	24
42	Characterizing the transitioning epidemiology of herpes simplex virus type 1 in the USA: model-based predictions. <i>BMC Medicine</i> , 2019 , 17, 57	11.4	41

41	Forecasting the impact of diabetes mellitus on tuberculosis disease incidence and mortality in India. <i>Journal of Global Health</i> , 2019 , 9, 020415	4.3	4
40	Hepatitis C Virus in the Middle East and North Africa 2019 , 1-27		2
39	Treatment as prevention for hepatitis C virus in Pakistan: mathematical modelling projections. <i>BMJ Open</i> , 2019 , 9, e026600	3	10
38	Characterizing the temporal evolution of the hepatitis C virus epidemic in Pakistan. <i>Journal of Viral Hepatitis</i> , 2018 , 25, 670-679	3.4	20
37	Use of routine HIV testing data for early detection of emerging HIV epidemics in high-risk subpopulations: A concept demonstration study. <i>Infectious Disease Modelling</i> , 2018 , 3, 373-384	15.7	4
36	Hepatitis C virus infection spontaneous clearance: Has it been underestimated?. <i>International Journal of Infectious Diseases</i> , 2018 , 75, 60-66	10.5	15
35	Impact of treatment on hepatitis C virus transmission and incidence in Egypt: A case for treatment as prevention. <i>Journal of Viral Hepatitis</i> , 2017 , 24, 486-495	3.4	46
34	Parameters identification for a model of T cell homeostasis. <i>Mathematical Biosciences and Engineering</i> , 2015 , 12, 917-36	2.1	
33	An Age-Structured Model for T Cell Homeostasis in Vivo. <i>SIAM Journal on Applied Mathematics</i> , 2014 , 74, 1463-1485	1.8	
32	Parameter identification for model of T cell proliferation in lymphopenia conditions. <i>Mathematical Biosciences</i> , 2014 , 251, 63-71	3.9	3
31	Protection afforded by prior infection against SARS-CoV-2 reinfection with the Omicron variant		8
30	Effectiveness of BNT162b2 and mRNA-1273 COVID-19 boosters against SARS-CoV-2 Omicron (B.1.1.529) infection in Qatar		3
29	Duration of protection of BNT162b2 and mRNA-1273 COVID-19 vaccines against symptomatic SARS-CoV-2 Omicron infection in Qatar		6
28	Waning of mRNA-1273 vaccine effectiveness against SARS-CoV-2 infection in Qatar		2
27	Protection offered by mRNA-1273 versus BNT162b2 vaccines against SARS-CoV-2 infection and severe COVID-19 in Qatar		2
26	Estimating protection afforded by prior infection in preventing reinfection: Applying the test-negative study design		4
25	Can the COVID-19 pandemic still be suppressed? Putting essential pieces together. <i>Journal of Global Health Reports</i> ,	1.1	2
24	Characterizing the effective reproduction number during the COVID-19 epidemic: Insights from Qatar's experience		1

23	Characterizing key attributes of the epidemiology of COVID-19 in China: Model-based estimations	11
22	Age could be driving variable SARS-CoV-2 epidemic trajectories worldwide	6
21	Epidemiological impact of SARS-CoV-2 vaccination: mathematical modeling analyses	17
20	Characterizing the Qatar advanced-phase SARS-CoV-2 epidemic	21
19	Assessment of the risk of SARS-CoV-2 reinfection in an intense re-exposure setting	36
18	Analyzing inherent biases in SARS-CoV-2 PCR and serological epidemiologic metrics	3
17	Evidence for and level of herd immunity against SARS-CoV-2 infection: the ten-community study	10
16	Mathematical modeling of the SARS-CoV-2 epidemic in Qatar and its impact on the national response to COVID-19	8
15	SARS-CoV-2 infection hospitalization, severity, criticality, and fatality rates	12
14	Effect of vaccination and of prior infection on infectiousness of vaccine breakthrough infections and reinfections	5
13	Estimates of global SARS-CoV-2 infection exposure, infection morbidity, and infection mortality rates	1
12	Epidemiological impact of prioritizing SARS-CoV-2 vaccination by antibody status: Mathematical modeling analyses	4
11	Protection afforded by the BNT162b2 and mRNA-1273 COVID-19 vaccines in fully vaccinated cohorts with and without prior infection	9
10	Waning of BNT162b2 vaccine protection against SARS-CoV-2 infection in Qatar	22
9	BNT162b2 and mRNA-1273 COVID-19 vaccine effectiveness against the Delta (B.1.617.2) variant in Qatar	32
8	Severity, criticality, and fatality of the SARS-CoV-2 Beta variant	2
7	SARS-CoV-2 vaccine effectiveness in immunosuppressed kidney transplant recipients	2
6	SARS-CoV-2 reinfection in a cohort of 43,000 antibody-positive individuals followed for up to 35 weeks	20

5	Protection of Omicron sub-lineage infection against reinfection with another Omicron sub-lineage	6
4	Effects of BA.1/BA.2 subvariant, vaccination, and prior infection on infectiousness of SARS-CoV-2 Omicron infections	3
3	Protection of prior natural infection compared to mRNA vaccination against SARS-CoV-2 infection and severe COVID-19 in Qatar	2
2	Duration of mRNA vaccine protection against SARS-CoV-2 Omicron BA.1 and BA.2 subvariants in Qatar	5
1	Effects of Previous Infection and Vaccination on Symptomatic Omicron Infections. <i>New England Journal of Medicine</i> ,	59.2 24